MARKET

ORMP

ORMP

Oramed Pharmaceuticals Inc
NASDAQ
3.550
+0.090
+2.60%
Closed 16:00 02/26 EST
OPEN
3.520
PREV CLOSE
3.460
HIGH
3.610
LOW
3.450
VOLUME
230.06K
TURNOVER
0
52 WEEK HIGH
5.25
52 WEEK LOW
1.670
MARKET CAP
143.20M
P/E (TTM)
-8.6396
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ORMP last week (0219-0223)?
Weekly Report · 1d ago
Oramed Pharmaceuticals CEO Updates Shareholders on Strategy
TipRanks · 02/20 13:52
Weekly Report: what happened at ORMP last week (0212-0216)?
Weekly Report · 02/19 10:37
MQ, ORMP and EXAI are among pre market gainers
MQ, ORMP and EXAI are among pre market gainers. DIH Holdings US (DHAI) +115%. Beamr Imaging (BMR) +72% NVIDIA team up to accelerate adoption of the newest video standard - AV1. ContextLogic (WISH) +38%.
Seeking Alpha · 02/12 13:34
Weekly Report: what happened at ORMP last week (0205-0209)?
Weekly Report · 02/12 10:30
Weekly Report: what happened at ORMP last week (0129-0202)?
Weekly Report · 02/05 10:35
Top 4 Health Care Stocks That May Crash This Quarter
As of Feb. 2, 2024, four stocks in the health care sector are considered overbought. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength when prices fall. An asset is typically considered over bought when the R SI is above 70, according to Benzinga.
Benzinga · 02/02 13:21
Weekly Report: what happened at ORMP last week (0122-0126)?
Weekly Report · 01/29 10:28
More
About ORMP
Oramed Pharmaceuticals Inc. is a pharmaceutical company, which is engaged in the research and development of pharmaceutical solutions with its technology platform. Its POD (Protein Oral Delivery) technology has been designed to protect orally delivered proteins from detrimental enzymatic activity within the gastrointestinal tract and to enhance their absorption across the intestinal wall. Its pipeline includes ORMD-0801 diabetes, ORMD-0901, and ORMD-0801 non-alcoholic steatohepatitis (NASH). Its flagship product, ORMD-0801, allows insulin to travel from the gastrointestinal tract via the portal vein to the liver. It is conducting Phase III trials in patients with type 2 diabetes. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone, that stimulates the secretion of insulin from the pancreas. It is also engaged in the research and development of an oral vaccine for COVID-19 through its subsidiary, Oravax Medical Inc.

Webull offers Oramed Pharmaceuticals, Inc. stock information, including NASDAQ: ORMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORMP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ORMP stock methods without spending real money on the virtual paper trading platform.